TY - JOUR
T1 - Effect of interleukins (Il-2, il-15, il-18) on receptors activation and cytotoxic activity of natural killer cells in breast cancer cell
AU - Widowati, Wahyu
AU - Jasaputra, Diana K.
AU - Sumitro, Sutiman B.
AU - Widodo, Mochammad A.
AU - Mozef, Tjandrawati
AU - Rizal, Rizal
AU - Kusuma, Hanna Sari W.
AU - Laksmitawati, Dian R.
AU - Murti, Harry
AU - Bachtiar, Indra
AU - Faried, Ahmad
N1 - Funding Information:
This study was supported by the Grants-in-Aid from Penelitian Dasar Unggulan Perguruan Tinggi (2018-2020) and Bantuan Seminar Luar Negeri 2018, the Ministry of Research, Technology and Higher Education of the Republic of Indonesia. The authors like to thank to Yukko Arinta, Annisa Amalia, Rismawati Laila Q, Fajar Sukma Perdana, Annisa Arlisyah, Jenifer Kiem Aviani and Ika Adhani Sholihah from Biomolecular and Biomedical Research Center, Aretha Medika Utama, Bandung, West Java, Indonesia for their technical assistants.
Publisher Copyright:
© 2020 Widowati W et al.Licensee African Health Sciences.
PY - 2020/6
Y1 - 2020/6
N2 - Introduction: Breast cancer is one of the leading cause of cancer deaths in women. Metastasis in BC is caused by immuno-surveillance deficiency, such NK cell maturation, low NK activity and decreasing cytotoxicity. This study was performed to improve activating receptors and cytotoxicity of NK cells using interleukins (ILs). Methods: Human recombinant IL-2,-15, and-18 were used to induce NK cells. We measured the activating and inhibiting receptors, proliferation activity of NK cells, and the cytotoxicity of NK cells on BC cells (MCF7). The effects of ILs were tested on the NK cell receptors CD314, CD158a and CD107a with flowcytometry, proliferation at various incubation times with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and concen-trations of TNF-α and IFN-γ by NK cells with ELISA. Results: ILs increased NK cell receptor levels (CD314, CD158a, and CD107a) at 24 hours of incubation. ILs increased NK cell viability, which increased with longer incubation. Moreover, ILs-induced NK cells inhibited proliferation in MCF7 cells, as well as increased TNF-α, IFN-γ, PRF1 and GzmB secretion. Conclusion: IL-2, IL-15, and IL-18 improved activating receptors and proliferation of NK cells. IL-induced NK cells increased TNF-α, IFN-γ, PRF1 and GzmB secretion and cytotoxic activity on BC cells. High NK cell numbers increased BC cell growth inhibition.
AB - Introduction: Breast cancer is one of the leading cause of cancer deaths in women. Metastasis in BC is caused by immuno-surveillance deficiency, such NK cell maturation, low NK activity and decreasing cytotoxicity. This study was performed to improve activating receptors and cytotoxicity of NK cells using interleukins (ILs). Methods: Human recombinant IL-2,-15, and-18 were used to induce NK cells. We measured the activating and inhibiting receptors, proliferation activity of NK cells, and the cytotoxicity of NK cells on BC cells (MCF7). The effects of ILs were tested on the NK cell receptors CD314, CD158a and CD107a with flowcytometry, proliferation at various incubation times with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxy methoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay and concen-trations of TNF-α and IFN-γ by NK cells with ELISA. Results: ILs increased NK cell receptor levels (CD314, CD158a, and CD107a) at 24 hours of incubation. ILs increased NK cell viability, which increased with longer incubation. Moreover, ILs-induced NK cells inhibited proliferation in MCF7 cells, as well as increased TNF-α, IFN-γ, PRF1 and GzmB secretion. Conclusion: IL-2, IL-15, and IL-18 improved activating receptors and proliferation of NK cells. IL-induced NK cells increased TNF-α, IFN-γ, PRF1 and GzmB secretion and cytotoxic activity on BC cells. High NK cell numbers increased BC cell growth inhibition.
KW - Activator
KW - Breast cancer
KW - Interleukins
KW - Natural killer
KW - Receptor
UR - http://www.scopus.com/inward/record.url?scp=85088591808&partnerID=8YFLogxK
U2 - 10.4314/ahs.v20i2.36
DO - 10.4314/ahs.v20i2.36
M3 - Article
C2 - 33163049
AN - SCOPUS:85088591808
SN - 1680-6905
VL - 20
SP - 822
EP - 832
JO - African Health Sciences
JF - African Health Sciences
IS - 2
ER -